Regeneron releases corporate presentation highlighting Q1 performance and drug pipeline updates

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals, Inc.

REGN

0.00
  • Regeneron posted Q1 2026 total revenue of USD 3.6 billion; non-GAAP EPS was USD 9.47.
  • Dupixent global net sales reached USD 4.9 billion, up 31% year over year.
  • EYLEA HD U.S. net product sales were USD 468 million; product represented about 50% of combined EYLEA and EYLEA HD U.S. sales.
  • FDA accepted garetosmab BLA for fibrodysplasia ossificans progressiva with priority review; PDUFA date set for August 2026.
  • Cemdisiran NDA for generalized myasthenia gravis was filed using a priority review voucher; FDA decision expected in Q4 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regeneron Pharmaceuticals Inc. published the original content used to generate this news brief on April 29, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.